COMP <GO>
SRTS vs MRK // NET PROFIT MARGIN
Sensus Healthcare Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SRTS 1
— MRK 10
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $2.76 (-0.36%) • MKT CAP: $45.6M
net-margins
-28.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRTS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRTS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 43.20% | 74.80% | -31.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.30% | 20.70% | -52.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.73% | 3.42% | -2.69 | MRK | /fcf-yield <GO> |
| Operating Margin | -37.50% | 34.30% | -71.80 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -28.10% | 28.10% | -56.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -34.30% | 1.30% | -35.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.50 | 5.19 | +1.31 | SRTS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 51.7 | -11.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.6M | $361.02B | -$360.98B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRTS REV | MRK REV | SRTS GROSS % | MRK GROSS % | SRTS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.5M | $65.01B | 43.2% | 74.8% | $332.0K | $12.36B |
| FY 2024 | $41.8M | $64.17B | 58.4% | 76.3% | -$1.1M | $18.10B |
| FY 2023 | $24.4M | $60.12B | — | — | -$2.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRTS // BETA —
MRK // BETA 0.92